The trade-off: rapid weight loss without anabolic signaling often leads to muscle catabolism alongside fat loss
Non-alcoholic fatty liver disease is a progressive disease, without effective intervention, can gradually deteriorate into non-alcoholic steatohepatitis, fatty liver fibrosis, liver cirrhosis and even liver cancer, and may become the main cause of end-stage liver disease in the future [11]
Drawing on continued Keytruda momentum, which continues its reign as the worlds best-selling drug with sales that rose 18% to $29.5 billion in 2024
Prolonged use without exercise or strength training can also strip away muscle along with fat
However, although commonly reported by patients, these symptoms are mostly mild, are rarely a reason for discontinuation of therapy, and seem to decrease over time with ongoing treatment.7,25e27 Although gastrointestinal side-effects occurred commonly in the large cardiovascular outcome trials, most were reported in the first weeks after initiation and they only led to discontinuation of treatment in 1e3% of cases.10,11 On the ICU, GLP-1 was also found to decrease gastric motility, although its effect was minimal when gastric emptying was already delayed.28 In patients with diabetes mellitus, gastroparesis is a known complication that requires attention and appropriate action by anaesthesiologists
